OPKO Health Inc. filed SEC Form 8-K: Leadership Update
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 27, 2025, the Compensation Committee of the Board of Directors (the “Committee”) of OPKO Health, Inc. (the “Company”) held a meeting to review certain compensation matters for the Company’s executive officers and non-executive employees. At the meeting, the Committee (i) granted stock options to the Company’s named executive officers (the “Officers”) to purchase the number of shares of the Company's common stock set forth opposite their names below and (ii) approved bonus payments to employees, including the Officers named below in the amounts set forth opposite their names. The stock options have an exercise price of $1.31 per share, vest ratably on an annual basis over four years, and expire on the tenth anniversary of the grant date.
Name |
|
Title |
|
Stock Options |
|
Bonus |
Phillip Frost, M.D. |
|
Chief Executive Officer/Chairman |
|
500,000 |
|
$480,000 |
Jane H. Hsiao, Ph.D. |
|
Vice Chairman/Chief Technical Officer |
|
500,000 |
|
$450,000 |
Elias A. Zerhouni, M.D. |
|
Vice Chairman/President |
|
500,000 |
|
$450,000 |
Steven D. Rubin |
|
Executive Vice President - Administration |
|
437,500 |
|
$400,000 |
Adam Logal |
|
Senior Vice President/Chief Financial Officer |
|
437,500 |
|
$475,000 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
OPKO Health, Inc. |
|
|
|
|
Date: |
May 29, 2025 |
By: |
/s/ Steven D. Rubin |
|
|
Name: |
Steven D. Rubin |
|
|
Title: |
Executive Vice President - Administration |